by Debu Tripathy,
Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Nadia Harbeck, Sara A
Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael
Villanueva Vazquez, Kyung Hae Jung, K Govind Babu, Paul Wheatley-Price,
Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir,
Mei-Ching Liu, Gary Carlson, Gareth Hughes, Ivan Diaz-Padilla, Caroline Germa,
Samit Hirawat, Yen-Shen Lu
The Lancet Oncology Vol 19, No. 7, p904-915, July
2018
Ribociclib plus
endocrine therapy improved progression-free survival compared with placebo plus
endocrine therapy, and had a manageable safety profile in patients with premenopausal,
HR-positive, HER2-negative, advanced breast cancer. The combination could
represent a new first-line treatment option for these patients.
See also comment… https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30367-X/fulltext?rss=yes
